Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus LOCOID.
CYCLOCORT vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid